Inicure AB is a Swedish biotech company developing a new class of immune-activating therapies to combat antibiotic-resistant infections. Our innovative small-molecule FPR1 agonists boost the body’s own immune response—offering a resistance-free alternative to traditional antibiotics. Founded in 2024 as a spin-off from Pronoxis AB and GU Ventures, Inicure is advancing promising preclinical compounds with strong efficacy and safety profiles, supported by leading academic and industry partners.
Company Details
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.inicure.com
- Keywords
- Gothenburg.
Inicure Ab Questions
Inicure Ab's website is http://www.inicure.com
Inicure Ab's LinkedIn profile is https://www.linkedin.com/company/inicure
Inicure Ab's industry is
Biotechnology Research
Inicure Ab's top competitors are
Irlab Therapeutics Ab,
Exocure Sweden Ab,
Elicera Therapeutics Ab,
Cereno Scientific,
Ectin Research.
Inicure Ab's categories are Biotechnology Research
